Venetoclax (Ven), a highly selective BCL-2 inhibitor, was FDA-approved in 2018 for treating newly diagnosed AML in elderly patients aged 75 years and up, in combination with DNA methyltransferase inhibitors [2]. Here, BCL2 is linked to acute myeloid leukemia.